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dementia, the perspective and inclusion of informal costs is essential. The research 
is funded by the European Commission, ICT FP7, project ID 287509.
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Objectives: Estimating resource use [RU] in real life is an important part of health 
economic evaluations. RU data should reflect how patients are actually treated. In 
MDD, RU data are mostly obtained from expert opinion. Variability in RU may lead to 
uncertainty in health economic evaluations, but few published studies report these 
data in the detail needed. The present analysis reports RU data by depression health 
state from an observational study. MethOds: PERFORM (Prospective Epidemiological 
Research on Functioning Outcomes Related to Major depressive disorder) is a 2-year 
prospective observational study conducted in 5 Western-European countries. Two- and 
six-month RU were estimated by health state: remitters, non-remitters, patients in 
relapse or not. RU included visits to different health care professionals, hospitalization 
and sick leave. Results are reported for the whole study population and are also avail-
able by country (including the UK, for which EQ5-D-derived utilities are also available) 
and for subgroups (e. g., patients who switched antidepressants at baseline). Results: 
Of the 819 analysable patients at 2 months, 29% were in remission. Among patients 
with at least one visit, the frequency of visits to general practitioners, psychiatrists 
and psychotherapists was consistently lower for remitters versus non-remitters (1.8 
vs. 2.4, 2.2 vs. 2.4 and 2.6 vs. 3.1 respectively). Fourteen patients had at least one hos-
pitalisation. Sick leave was less frequent (14% vs. 27%) and shorter (34 vs. 41 days) for 
remitters versus non-remitters respectively. At 6 months, 19.3% of patients relapsed. 
RU were higher with more visits to psychiatrists, psychotherapists (4.0 vs. 2.7, 7.8 
vs. 5.5) for relapsed versus non-relapsed patients. cOnclusiOns: This first analysis 
provides European RU data in MDD. More information is expected at completion of 
the two-year follow-up and this study offers the possibility to describe RU by health 
states, countries and subgroups and assess their transferability to other countries.
PMH69
tHE iMPact of EconoMic crisis on suicidE ratEs in GrEEcE
Skroumpelos A.1, Zavras D.1, Kyriopoulos I.I.1, Nikolaidis G.2, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Institute of Child Health, Athens, Greece
bAcKGROund And Objectives: Economic crisis in Greece has several social impli-
cations, as unemployment and poverty have largely increased during the past years. 
Since the onset of the economic crisis, suicides have marked a significant increase. 
Therefore, aim of this study is to investigate the relationship between suicides and 
the economic crisis and certain macroeconomic indices. MethOds: Annual suicide 
rates were obtained from the Hellenic Statistical Authority. Multiple linear regres-
sion analysis with Newey-West standard errors was carried out in order to examine 
the relationship between gender and age specific suicide rates and unemployment, 
GDP per capita and economic crisis (binary variable). Additionally, several statistical 
tests were conducted in order to examine the properties and the robustness of the 
model. Results: Unemployment appears as the major factor affecting suicides of 
men and women above the age of 15. However, gender and age-related differences are 
being observed. Unemployment is positively associated with the suicides of men aged 
15-24, 35-44, 55-64 years. Female suicides are also affected by unemployment, exclud-
ing the age groups of 35-44 and 45-54 years old. Interestingly, suicides of women aged 
between 45-54 and 55-64 were negatively associated with economic crisis. In the total 
population, unemployment has impact on suicides for 15-24, 35-44, 55-64 age groups, 
while economic crisis affects suicide rate in the age group of 25-34. In addition, GDP 
per capita is negatively associated with suicide rates for young men (aged under 24). 
The same effect is also observed for the young population in general. cOnclusiOns: 
The current economic turmoil in Greece affects suicides deaths. According to this 
analysis, unemployment is the main factor that determines age-specific rates and 
essentially point to the direction where measures should be taken in order to control 
suicides’ incidence and lessen the effect of economic crisis on health.
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Objectives: Population-based approaches to improving health are critical to con-
trolling rising health care costs. US Veterans represent an identifiable population of 
significant interest due to their unique occupational exposures. The objectives of this 
study is to characterize the mental health of a representative US sample specifically 
comparing: non-Veterans, Veterans receiving VA benefits and Veterans not receiving 
VA benefits. MethOds: A representative (U.S. ) sample of 2,000 individuals completed 
an online survey assessing their mental health (PHQ-2), Veteran status and receipt of 
Veteran Administration health care benefits. We conducted bivariate analyses among 
the entire population and multivariate logistic regression among 352 Veterans to 
assess the relationship between ones mental health (PHQ-2 score > = 3) and Veteran 
benefit enrollment status controlling for ones self-reported physical health, history 
of combat, awareness of Veteran Crisis Line and sociodemographic factors. Results: 
Overall 28% of Veterans scored positive for depressive symptom based on a score 
of 3 or greater on the PHQ-2 compared to 11% of non-Veterans. However, breaking 
Veterans into those enrolled and those not enrolled revealed that 38% of enrolled 
Veterans were positive compared to just 17% of non-enrolled Veterans. After removing 
insignificant and/or collinear variables from the logistic regression model, the final 
set of independent variables included Vets enrolled in VA benefits OR= 3.91 (1.93- 8.44), 
poor/fair physical health OR= 4.32 (1.98-9.68), age OR= 0.93 (0.91-0.95) and awareness 
of Veteran crisis line 3.12 (1.69- 5.97). cOnclusiOns: Younger veterans in poorer 
physical health whom are receiving VA benefits and are aware of the Veteran Crisis 
line are more likely to have depressive symptoms. Population based approaches to 
linkage between the pharmaceutical database and the SANIARP database, using 
anonymized patient code. Based on the date of the first prescription (index date) 
the following prescribing patterns have been defined: continuers (subjects with 
a gap < 30 days between two prescriptions on-going); intermittent (subjects with 
a gap> 30 days but that receive another prescription at index date); switchers 
(discontinuation of index drug and prescription of a new antipsychotic); add-on 
(addition of a new antipsychotic); as-needed (addition of a new antipsychotic for 
a limited period). Results: We identified 2,768 patients (44.5% females) with at 
least one prescription of atypical antipsychotics and with a diagnosis coded in 
the study period. Schizophrenia is the most frequent indication (31.1%) the most 
prescribed drug is olanzapine (29.1%), followed by risperidone (17.7%), quetiapine 
(13.4%), aripiprazole (12.5%), clozapine (10.3%) and asenapine (3.1%). About 70% of 
schizophrenic patients is treated with the same drug, 7.9% switch and 23.6% is in 
polytherapy. cOnclusiOns: The use of SANIARP, web- platform able to allow the 
systematic monitoring of prescribing patterns of drugs, is of primary importance 
for better health planning.
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Objectives: Major Depressive Disorders (MDD) guidelines recommend using 
antidepressants with dual mechanism-of-action (venlafaxine, duloxetine) when 
resistant to a prior course of Selective-Serotonin-Reuptake-Inhibitors (SSRI). Dose 
to use should be close to the DDD recommended by WHO. Routine clinical prac-
tice may be frequently far from guidelines. The aim was to ascertain the average 
maintenance daily dose (DD) of venlafaxine and duloxetine in the monotherapy 
of patients with MDD who showed resistance to a previous SSRI in routine medi-
cal practice in Spain. MethOds: Retrospective analysis extracting consecutively 
electronic medical records (EMR) of the BSA, a provider which health plan coverage 
includes near 120,000 inhabitants in Badalona (Spain). EMR of male/female patients, 
> 18 years, included in the chronic prescription follow up program, with a MDD 
ICD-9-CM code (296.2x/296.3x), and who were resistant to a previous SSRI course, 
were extracted for analysis. Resistant was defined as persistence of symptoms 
(score > 17 in the Hamilton-Depression scale and/or reduction lower than 30% of the 
baseline score). Maintenance DD was considered the dose repeated (refills) at least 
two time consecutively during the study period (years 2012-2013). Results: Three-
sixty-eight EMR [81% women, 60.3 (15.2) years] were extracted; 160 of duloxetine 
and 208 of venlafaxine. Average maintenance DD were 65mg/day and 117 mg/day 
for duloxetine and venlafaxine, respectively. Demographics, number of comorbidi-
ties or previous SSRI were not related with average dose. 86% of duloxetine EMR 
were prescribed the WHO DDD for this drug (60mg), while only 42% of venlafaxine 
received its WHO DDD (100mg), p< 0.001. Number of DDD per day were significantly 
higher with venlafaxine; 1.17 (1.10-1.23) vs. 1.09 (1.05-1.12), p= 0.049. cOnclusiOns: 
Routine medical practice average maintenance DD of venlafaxine and duloxetine in 
SSRI resistant subjects with MDD are different in terms of both their recommended 
doses in labelling or guidelines and in number of DDD per day.
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Objectives: Dementia patients are in need of more extensive personal care com-
pared to other long-term care users. This results in a high economic impact of demen-
tia on patients, families and health care systems. Due to the increasing prevalence 
of dementia worldwide, combined with limited health care expenditures, a better 
understanding of resource use in dementia care is needed. Therefore the aim of our 
study is the assessment of resource use in dementia in the most common setting: 
home-based care (informal caregivers). MethOds: The Erlanger Dementia Registry 
structure was set up in 2013. Both dementia patients and informal caregivers are 
interviewed separately with internationally approved valid instruments. Follow-up 
takes place after 6, 12 months and afterwards annually. Resource use in dementia is 
assessed via the ‘Resource Utilization in Dementia (RUD) instrument’. Results: A 
total number of 50 informal caregivers (mean age= 63, 61% female, 23% employed, 72% 
live together with the patient) were interviewed after the initial dementia diagnosis 
at baseline, and 22 study participants took part at the 1st follow-up. Informal caregiv-
ers were mainly spouses (72%) and children (22%). Main support was provided for 
instrumental activities of daily living (t0:77%; t6:86%), followed by activities of daily 
living (t0:37%; t6:52%) and supervision (t0:26%; t6:33%). Average hours for support 
6 months after diagnosis were: IADL= 4.3h/day (min= 1.0, max= 16.0), ADL= 5,2h/day 
(min= 2.0, max= 16.0), and supervision= 12.9h/day (min= 1.0, max= 24.0). The average 
monthly costs for informal caregivers 6 months after diagnosis (medication; addi-
tional disease-related costs) are 76 € . cOnclusiOns: Our results highlight the sig-
nificant impact of informal costs (time provided for care) in dementia care, occurring 
early in the disease course. For dementia patients cared for at home, informal costs 
put an additional economic burden on families. For future health policy planning in 
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13 years (children) [22.7%], 13-17 years (adolescents) [17.3%], 18-40 years [30.0%], and 
> 40 years [30.0%]. The prevalence of HbA1c, FBS, and lipid panel testing significantly 
differed among the groups overall, and increased with increasing age, for both FGAs 
and SGAs. cOnclusiOns: It is recommended that patients taking antipsychotics 
be tested regularly for glucose and lipid changes. Only about one-third of patients 
taking antipsychotic medications had a lipid panel test, and less than one-fifth had 
an HbA1c or FBS test during the 12 months of analysis.
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Objectives: To describe and compare treatment patterns and health care costs in 
patients with schizophrenia initiating treatment with first-generation antipsychotic (s) 
(FGA) and patients initiating treatment with second-generation antipsychotic (s) 
(SGA) using claims database in Japan. MethOds: Using data from the Japan Medical 
Data Center (JMDC) database, a retrospective longitudinal cohort study was con-
ducted, including adults aged 18-65 years with a first prescription of antipsychotic 
(index date) between January 2009 and September 2013, and diagnosed with schiz-
ophrenia around index date. Time to treatment discontinuation (gap of 90 days 
without antipsychotic treatment), time to switch, time to psychiatric hospitalisation 
and total costs at 6 and 12 months were estimated for each group (FGA vs. SGA), 
and compared, with adjustment on potential confounders (gender, age, insurance 
status, index year and baseline costs) using Cox proportional-hazards regression 
and log-linear regression models. Results: 2,615 patients were included (14% ini-
tiating treatment with FGA and 86% initiating with SGA). 55.0% were female, with 
no significant difference between the groups (p= 0.22). FGA patients were older than 
SGA patients (40.1 years vs. 34.1, p< 0.0001). The total health care costs at 6 months 
were significantly higher in FGA patients (¥1,489,680 vs. ¥324,595; p< 0.0001). After 
adjustment, FGA treatment was associated with higher costs at 6 months (+121%, 
IC95%: [+93%; +152%], p< 0.0001), and at 12 months (+87%, IC95%: [+60%; +119%], 
p< 0.0001). Time to discontinuation as well as time to hospitalisation were shorter 
for the FGA group but did not reach significance (HR= 1.146, p= 0.09; HR= 1.406, p= 0.07 
respectively). The probability of switching was higher in the FGA group (HR: 5.281, 
p< 0.0001). cOnclusiOns: A large proportion of patients with schizophrenia were 
treated with SGA at initiation, consistently with previous studies conducted in 
Japan. Patients treated with SGA tend to have longer treatment duration and lower 
costs than patients treated with FGA.
urinary/kidnEy disordErs – clinical outcomes studies
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Objectives: To compare the efficacy and tolerability of oral first-line antimus-
carinic agents recommended for the treatment of OAB. MethOds: Literature 
searches were undertaken to identify published randomised controlled trials 
(2000–2012), which reported efficacy and/or tolerability in adults receiving phar-
macological treatment for OAB. Bayesian MTC methodology was used to assess 
changes from baseline in micturition frequency per 24h, urgency, incontinence, 
and urge incontinence (UI). Safety outcomes included dry mouth, constipation, and 
blurred vision. Results: Forty-one eligible trials involving 25,118 patients were 
included in the MTC. Solifenacin 5mg was significantly more effective than darifena-
cin 7.5mg based on incontinence (mean difference [MD]= 0.531/day), fesoterodine 
4mg based on micturition (MD= 0.374/day), and tolterodine 4mg based on micturi-
tion (MD= 0.387/day), urgency (MD= 0.434/day), incontinence (MD= 0.309/day), and 
UI (MD= 0.416/day). However, the starting dose of solifenacin 5mg was significantly 
less effective than solifenacin 10mg according to micturition (MD= –0.343/day), and 
urgency (MD= –0.391/day). No other significant efficacy differences were reported. 
Solifenacin 5mg had a significantly lower risk of dry mouth compared to oxybutynin 
(intermediate-release) IR 9mg (odds ratio [OR]= 2.732) or 10mg (OR= 3.534), oxybu-
tynin extended-release (ER) 10mg (OR= 1.714), tolterodine IR 4mg (OR= 1.763), and 
solifenacin 10mg (OR= 2.470). Tolterodine ER 4mg (OR= 0.481) or IR 4mg (OR= 0.440), 
oxybutynin IR 9mg (OR= 0.429) or ER 10mg (OR= 0.440), and fesoterodine 4mg 
(OR= 0.463) were associated with a significantly lower risk of constipation than 
solifenacin 5mg. Solifenacin 10mg was associated with a higher risk of constipation 
(OR= 1.804) and blurred vision (OR= 1.730) than solifenacin 5mg. cOnclusiOns: 
This MTC suggests that the 5mg starting dose of solifenacin is more effective than 
the 4mg starting dose of tolterodine in reducing symptoms of OAB; solifenacin 5mg 
also has similar or better efficacy than the starting doses of other antimuscarinic 
agents across the spectrum of symptoms analysed. The lower risk of dry mouth with 
solifenacin 5mg may deliver improved treatment persistence.
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identifying Veterans at risk for poor mental health may be working to provide health 
care benefit coverage but the persistence of symptoms, amongst those enrolled, may 
suggest a need for improved treatment or surveillance.
PMH71
History of antidEPrEssant usE aMonG PriMary carE dEPrEssEd 
PatiEnts switcHinG trEatMEnts in tHE unitEd kinGdoM
Lamy F.X.1, Quelen C.1, Brignone M.1, Ferchichi S.2, Vataire A.L.2, Rive B.1, Saragoussi D.1
1Lundbeck SAS, Issy-les-Moulineaux, France, 2Creativ-Ceutical, Paris, France
Objectives: Major depressive disorder is characterised by the presence of one 
or more major depressive episodes. Up to one-third of patients do not adequately 
respond to first-line therapies. In case of treatment failure, the most common strat-
egy is to switch to another antidepressant drug (AD). However, patients may have 
been exposed in prior episodes to one or more other ADs, which could impact 
the efficacy of subsequent treatments. This study describes historical AD use in 
depressed patients undergoing treatment switch. MethOds: This retrospective lon-
gitudinal cohort study used a database of medical records from general practition-
ers located throughout the UK (CPRD). Adult patients with a depression diagnosis 
undergoing an AD switch between 01/01/2012 and 30/06/2013 and with no diagnosis 
of schizophrenia or bipolar disorder were included. Historical AD use was assessed 
on all available prescriptions prior to switch and was grouped by treatment class 
(SSRI, SNRI, TCA and others). Results: 11,611 patients were identified. Their mean 
age was 44.5 years (SD= 16.18) and 66.7% were women. Prior to switch, patients used 
2.65 different classes of ADs on average (SD= 1.89); at least two different classes of 
ADs were prescribed for 64.8% of patients. Before the switch, SSRIs were the most 
common (1.65/patient) followed by TCAs (0.51/patient), other ADs (0.31/patient) 
and SNRIs (0.18/patient). Significant proportions of patients had previously been 
prescribed several AD classes: 34.1% of patients received at least one SSRI and one 
TCA, 24.0% at least one SNRI and one TCA, 15.0% at least one SSRI and one SNRI, 
and 13.7% at least one TCA and one other AD prior to AD switch. cOnclusiOns: 
This analysis showed that for patients initiating an AD switch, historical use of ADs 
was very common, and that a substantial proportion of patients had already been 
prescribed several ADs, thereby reducing the treatment options for future switches.
PMH72
trEatMEnt PattErns and HEaltH carE costs in PatiEnts witH 
dEPrEssion trEatEd witH antidEPrEssant only or coMBinEd witH 
BEnzodiazEPinE: rEsults froM a jaPanEsE claiMs dataBasE analysis
Jamotte A.1, Clay E.1, Onishi Y.2, Aballéa S.1, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Sanofi K.K., Tokyo, Japan, 3University of Marseille,  
Marseille, France
Objectives: To describe and compare treatment patterns and health care costs in 
patients with depression initiating treatment with antidepressant (AD) (in mono-
therapy or in combination) and patients initiating AD treatment combined with 
benzodiazepine (BZD) using claims database in Japan. MethOds: Using data from 
the Japan Medical Data Center (JMDC) database, a retrospective longitudinal cohort 
study was conducted, including adults aged 18-65 years with a first prescription 
of AD (index date) between January 2009 and September 2013, and diagnosed with 
major depression around index date. Time to treatment discontinuation (gap of 90 
days without AD treatment) and total costs at 6 and 12 months were estimated for 
each group (AD vs. AD+BZD), and compared, with adjustment on potential con-
founders (gender, age, insurance status, index year and baseline costs) using Cox 
proportional-hazards regression and log-linear regression models. Results: 7,723 
patients were included (43.7% initiating treatment with AD+BZD and 56.3% initiat-
ing with AD). Mean age of the population was 36.5 years and 59.1% were males, with 
no significant differences found between the groups (p= 0.14 and p= 0.39 respec-
tively). The total health care costs at 6 months were significantly higher in AD+BZD 
patients (¥176,946 vs. ¥151,992; p< 0.0001). After adjustment, AD+BZD treatment was 
associated with higher costs at 6 months (+5.2%, IC95%: [+4.7 %; +5.8 %], p< 0.0001) 
and at 12 months (+6.4%, IC95%: [+5.7%; +7.1%], p< 0.0001). Time to discontinuation 
was longer for the AD+BZD group (HR= 0.758, p< 0.0001). cOnclusiOns: A large 
proportion of patients with depression were treated with AD+BZD at initiation, a 
practice not recommended in Japanese guidelines. Patients treated with AD+BZD 
tend to have higher costs than patients treated with AD. The combination with BZD 
is associated with longer treatment duration and further analyses are recommended 
to determine if this is related to improved persistence or longer time to remission.
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Objectives: Patients taking antipsychotics are at higher risk for other co-morbid 
diseases, including metabolic-related conditions. The objective of this study was to 
determine the level of testing for potential medication-related co-morbidities, looking 
at rates of Hemoglobin A1c (HbA1c) and fasting blood sugar (FBS) tests for diabetes as 
well as lipid panel tests for hyperlipidemia. MethOds: Using Texas Medicaid claims 
for 2012, a total of 135,757 patients filled at least one prescription for an antipsychotic 
medication. Claims data on lab testing were extracted for these patients. Results: 
Overall, 36.0% of patients taking antipsychotics received a lipid panel test, 18.7% 
received an HbA1c test, and only 6.5% received a FBS test. Nine percent and 95.8% of 
patients had claims for first- and second-generation antipsychotics (FGAs and SGAs), 
respectively [some patients had both prescribed]. A total of 53.5% were male and 46.5% 
were female. A larger proportion of patients taking FGAs had HbA1c, FBS, and lipid 
panel tests compared to patients taking SGAs: 28.9% vs. 18.4% (HbA1c); 8.1% vs. 6.4% 
(FBS); 49.8% vs. 35.6% (lipid panel). A larger proportion of females had HbA1c, FBS, 
and lipid panel tests compared to males: 23.4% vs. 14.8% (HbA1c); 7.6% vs. 5.6% (FBS); 
40.7% vs. 32.3% (lipid panel). In addition, patients were divided into four age groups: < 
